Perspective Therapeutics price target raised to $13 from $11 at B. Riley

B. Riley raised the firm’s price target on Perspective Therapeutics (CATX) to $13 from $11 and keeps a Buy rating on the shares. Sentiment on Perspective Therapeutics has sharply improved after Sanofi (SNY) deprioritized AlphaMedix, shifting the narrative to VMT-alpha-NET as the sole meaningful competitor in NETs, with the company raising $175M to fund operations into late 2027, the analyst tells investors in a research note. Looking ahead, longer follow-up and higher-dose data expected at ASCO 2026 will be critical to demonstrating not just durable but superior responses versus Lutathera, strengthening the case for VMT-alpha-NET as a potential new standard of care, the firm says.